Director/Senior Director, Finance Controller

Full-Life Technologies; Boston (MA); On-site; USD 180,000 - 240,000; Full time

Job summary

Full-Life Technologies in Boston, MA, is seeking a Director/Senior Director of Finance / Controller to lead US GAAP accounting, close processes, and SEC reporting infrastructure for an IPO-ready biotech company. You will coordinate with external auditors and SEC counsel, build internal controls (SOX/ICFR), and drive readiness for registration statements, annual reports, and ongoing SEC filings post-IPO.

The role requires a US CPA, 10+ years in accounting (biotech preferred), and hands-on

Qualifications

• Active US CPA license.
• 10+ years progressive accounting experience in biotech or life sciences.
• Experience with S-1 registration and SEC reporting.
• Hands-on US GAAP knowledge for biotech accounting, including revenue and stock-based compensation.
• Experience managing relationships with PCAOB-registered audit firms.

Responsibilities

• Own US GAAP accounting positions and memos, including revenue recognition, R&D/collaboration and licensing accounting, stock-based compensation, and complex financing instruments.
• Lead preparation of financial statements in accordance with US GAAP and SEC requirements.
• Manage monthly/quarterly close process, ensuring timeliness and audit-readiness.
• Lead SEC filings including S-1, 10-K, 10-Q, 8-K, and proxy materials post-IPO.
• Build ICFR, document internal controls, and support SOX readiness.
• Coordinate with auditors, legal counsel and bankers on registrations and SEC reviews.

Skills

US GAAP expertise

Technical writing

SOX readiness

Audit liaison

Cross-functional collaboration

Education

Active US CPA license

10+ years accounting experience

Public company SEC reporting (S-1/10-K/10-Q) experience

Tools

ERP systems

Job description

Full-Life Technologies is a fully integrated global radiopharmaceutical company developing targeted radiotherapeutics for oncology.

With operations across the US, Europe and China, the company is building capabilities across the radiopharmaceutical value chain, including research and development, manufacturing, and commercialization, to bring innovative therapies to patients with cancer.

Full-Life's pipeline is built on differentiated radionuclide drug conjugate platforms and includes oncology programs in areas such as prostate cancer and other solid tumors.

Position Summary

The Director/Senior Director of Finance / Controller will be a key member of the finance leadership team, responsible for building and running the company's accounting close, technical accounting positions, and SEC reporting infrastructure. This role will serve as the primary liaison with external auditors (including PCAOB-registered firms) and outside SEC counsel, and will be instrumental in IPO readiness workstreams including internal controls (SOX), audit committee support, and public-company reporting cadence.

Key Responsibilities

Technical Accounting & Financial Reporting

• Own US GAAP technical accounting positions and memos, including revenue recognition, R&D/collaboration and licensing arrangements, stock-based compensation, and complex equity/debt instruments common in biotech financings
• Lead preparation of financial statements in accordance with US GAAP and SEC requirements
• Manage and continuously improve the monthly/quarterly close process, ensuring accuracy, timeliness, and audit-readiness

SEC Reporting & IPO Readiness

• Lead preparation of SEC filings including S-1 (and subsequent amendments), 10-K, 10-Q, 8-K, and proxy materials post-IPO
• Partner with legal counsel, investment bankers, and auditors on registration statement drafting, comment letter responses, and SEC review process
• Build out and document internal controls over financial reporting (ICFR) in anticipation of SOX 404 compliance
• Support drafting of MD&A, financial statement footnotes, and non-GAAP reconciliations
• Serve as primary day-to-day liaison with the company's PCAOB-registered independent auditor, managing the annual audit and interim reviews
• Proactively identify and resolve complex accounting issues ahead of audit fieldwork; prepare technical position papers for auditor review
• Support Audit Committee reporting and materials
• Coordinate any historical audit matters relevant to registration (e.g., re-audits, PCAOB-compliance considerations for prior periods)

Team & Process Build-Out

• Design and scale accounting policies, procedures, and the chart of accounts appropriate for a public biotech company
• Evaluate and implement accounting systems/ERP suited to public-company reporting needs
• Build, mentor, and eventually manage an accounting team as the company scales post-IPO

Qualifications

Required

• Active US CPA license
• 10+ years progressive accounting experience, including a mix of public accounting (Big 4 or national firm strongly preferred) and industry
• Direct experience in the biotechnology or life sciences industry (pre-commercial/clinical-stage strongly preferred)
• Hands-on experience with an S-1 registration process and/or public company SEC reporting (10-K/10-Q)
• Deep working knowledge of US GAAP as applied to biotech: revenue recognition, R&D expense, collaboration/licensing accounting, stock compensation, and complex financing instruments
• Experience directly managing relationships with PCAOB-registered audit firms
• Strong understanding of internal controls / SOX readiness

Preferred

• Experience with an IPO, de-SPAC, or direct listing transaction from the finance/accounting side
• Experience implementing or upgrading ERP/reporting systems in a scaling environment
• Prior experience working alongside investment bankers and outside SEC/capital markets counsel

Attributes

• Comfortable operating in a lean, fast-moving pre-IPO environment while building institutional-grade processes
• Strong technical writing skills for accounting memos and disclosure drafting
• High attention to detail balanced with ability to prioritize under public-company deadlines
• Collaborative, low-ego style able to work cross-functionally with legal, clinical, and executive teams